Back to results
US 10,590,077 B2Granted
TRPV4 antagonists
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsEdward J. Brnardic, Carl A. Brooks, Brian W. Budzik, Brian Griffin Lawhorn, Jay M. Matthews, John Jeffrey McAtee, Joseph E. Pero, David J. Behm
Life of this patent
Estimating the term…
Abstract
The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
Claims20
A compound according to Formula I:
- wherein:
- R1 is selected from:
- aryl,
- aryl substituted from 1 to 4 times by Ra,
- heteroaryl,
- heteroaryl substituted from 1 to 4 times by Ra,
- bicycloheteroaryl, and
- bicycloheteroaryl substituted from 1 to 4 times by Ra;
- R2 is selected from:
- aryl,
- aryl substituted from 1 to 4 times by Rb,
- heteroaryl,
- heteroaryl substituted from 1 to 4 times by Rb,
- bicycloheteroaryl, and
- bicycloheteroaryl substituted from 1 to 4 times by Rb, and
- Y1 is selected from:
- C1-6alkyl, and
- C1-6alkyl substituted with from:
- 1 to 9 substitutents independently selected from:
- fluoro,
- chloro,
- bromo,
- iodo,
- —OC1-6alkyl,
- —OC1-6alkyl substituted with from 1 to 6 substituents independently selected from:
- fluoro, oxo, —OH, —COOH, —NH2, and —CN,
- mercapto,
- —S(O)H,
- —S(O)2H,
- oxo,
- hydroxy,
- amino,
- —NHRx11,
- where Rx11 is selected from C1-6alkyl, and C1-6alkyl substituted with from 1 to 6 substituents independently selected from:
- fluoro, oxo, —OH, —COOH, —NH2, —CN, —OC1-5alkyl, —OC1-5alkyl substituted from 1 to 6 times by fluoro and —NH2,
- —NRx12Rx13,
- where Rx12 and Rx13 are each independently selected from C1-6alkyl, and C1-6alkyl substituted with from 1 to 6 substituents independently selected from:
- fluoro, oxo, —OH, —COOH, —NH2, and —CN,
- —C(O)OH,
- —C(O)NH2,
- aryl,
- —Oaryl,
- heteroaryl,
- —Oheteroaryl,
- —S(O)2NH2,
- —NHS(O)2H,
- nitro, and
- cyano, or
- Y1 is taken together with the adjacent —OH to form a heterocyclic ring selected from:
- morpholinyl,
- morpholinyl substituted by —CH3, and
- oxazolidin-2-one;
- each Ra is independently selected from:
- fluoro,
- chloro,
- bromo,
- iodo,
- —OH,
- C1-6alkyl,
- C1-6alkyl substituted with from 1 to 5 substituents independently selected from:
- fluoro, chloro, bromo, iodo, C1-6alkyloxy, —OH, C1-4alkyl, phenyl, oxo, —COOH, —NO2, —NH2 and —CN,
- cyano,
- —OC1-6alkyl,
- —OC1-6alkyl substituted with from 1 to 5 substituents independently selected from:
- fluoro, chloro, bromo, iodo, C1-6alkyloxy, —OH, C1-6alkyl, phenyl, oxo, —COOH, —NO2, —NH2 and —CN,
- —Ophenyl,
- —C(O)OC1-6alkyl,
- —C(O)OC1-6alkyl substituted 1 to 5 times by fluoro, and
- —Ocycloalkyl;
- and
- each Rb is independently selected from:
- fluoro,
- chloro,
- bromo,
- iodo,
- —OH,
- C1-6alkyl,
- C1-6alkyl substituted with from 1 to 5 substituents independently selected from:
- fluoro, chloro, bromo, iodo, C1-6alkyloxy, —OH, C1-4alkyl, phenyl, oxo, —COOH, —NO2, —NH2 and —CN,
- cyano,
- —OC1-6alkyl,
- —OC1-6alkyl substituted with from 1 to 5 substituents independently selected from:
- fluoro, chloro, bromo, iodo, C1-6alkyloxy, —OH, C1-4alkyl, phenyl, oxo, —COOH, —NO2, —NH2 and —CN,
- phenyl,
- —C≡C—Si(CH3)3, and
- —C≡C-cycloalkyl;
- or a pharmaceutically acceptable salt thereof.
84 more elements
Dependencies are inferred from the claim text.